Hematologists Highlight Ongoing Challenges in Sickle Cell Disease and Thalassemia Amidst Promising Advances in Gene Therapies
28 août 2024 10h14 HE
|
Spherix Global Insights
EXTON, PA, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Despite advancements in treatments, sickle cell disease and thalassemia continue to present significant challenges for patients and healthcare providers....
American Institutes for Research To Help Implement Federal Program Aimed at Increasing Access to Transformative Cell and Gene Therapy Treatments
21 août 2024 12h00 HE
|
American Institutes for Research
Arlington, Va., Aug. 21, 2024 (GLOBE NEWSWIRE) -- The American Institutes for Research (AIR) has been awarded a federal contract to help implement and monitor a new program that seeks to make...
Global Sickle Cell Anemia Testing & Screening Market Analysis and Forecast 2024-2030 - Rising Focus on Development of Non-Invasive, Hand-Held, and Digital Technologies
14 juin 2024 05h23 HE
|
Research and Markets
Dublin, June 14, 2024 (GLOBE NEWSWIRE) -- The "Global Sickle Cell Anemia Testing & Screening Market by Technology (Hemoglobin Electrophoresis, High-performance Liquid Chromatography (HPLC),...
Spherix Global Insights Expands Therapeutic Area Coverage into Hematology
10 juin 2024 04h00 HE
|
Spherix Global Insights
EXTON, PA, June 10, 2024 (GLOBE NEWSWIRE) -- Spherix Global Insights, a leading independent market intelligence and advisory firm that delivers commercial value to the global life sciences industry,...
CASGEVY Gets Bahrain approval for treatment, marking it second country in the world
02 déc. 2023 12h59 HE
|
National Health Regulatory Authority
CASGEVY Gets Bahrain approval for treatment, marking it second country in the world
AB Science tiendra une conférence virtuelle le jeudi 30 novembre 2023, de 15h à 16h, pour présenter le programme de développement clinique du masitinib dans la drépanocytose.
28 nov. 2023 13h22 HE
|
AB Science
COMMUNIQUE DE PRESSE AB SCIENCE TIENDRA UNE CONFERENCE VIRTUELLE SUR LE JEUDI 30 NOVEMBRE 2023, DE 15H A 16H, SUR LE PROGRAMME DE DEVELOPPEMENT CLINIQUE DU MASITINIB DANS LA DREPANOCYTOSE Paris, 28...
AB Science will host a live webcast on Thursday November 30, 2023, from 3pm to 4pm CET, to present the masitinib development program in sickle cell disease
28 nov. 2023 13h22 HE
|
AB Science
PRESS RELEASE AB SCIENCE WILL HOST A LIVE WEBCAST ON THE MASITINIB DEVELOPMENT PROGRAM IN SICKLE CELL DISEASE ON THURSDAY NOVEMBER 30, 2023, FROM 3PM TO 4PM CET Paris, 28 november, 2023, 7.15pm CET ...
AB Science : Le développement clinique du masitinib dans la drépanocytose fait partie des 19 projets lauréats dans le cadre du 6eme appel à projet RHU
27 nov. 2023 02h04 HE
|
AB Science
COMMUNIQUE DE PRESSE LE DEVELOPPEMENT CLINIQUE DU MASITINIB DANS LA DREPANOCYTOSE, UNE MALADIE GENETIQUE TRES REPANDUE, FAIT PARTIE DES 19 PROJETS LAUREATS DANS LE CADRE DU SIXIEME APPEL A PROJETS...
AB Science: The clinical development of masitinib in sickle cell disease is among the 19 winning projects under the sixth call for “Hospital-Inuversity Research in health (RHU)”
27 nov. 2023 02h04 HE
|
AB Science
PRESS RELEASE THE CLINICAL DEVELOPMENT OF MASITINIB IN SICKLE CELL DISEASE, A HIGHLY PREVALENT GENETIC CONDITION, IS AMONG THE 19 WINNING PROJECTS UNDER THE SIXTH CALL FOR "HOSPITAL-UNIVERSITY...
Malaria and Sickle Cell Disease Treatment Market Worth $29.17 Billion, Globally, by 2030 - Exclusive Report by The Insight Partners
03 nov. 2023 08h33 HE
|
The Insight Partners
Pune, India, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Sickle cell disease (SCD) is the most common inherited blood disorder that affects the red blood cells. Treatments for SCD can relieve pain and help...